Aquestive Therapeutics (NASDAQ:AQST) Stock: Insider Richard Daly Buys 28,025 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) Director Richard Daly bought 28,025 shares of Aquestive Therapeutics stock in a transaction on Tuesday, November 10th. The stock was acquired at an average price of $3.54 per share, with a total value of $99,208.50. Following the completion of the purchase, the director directly owned 28,025 shares of the company’s stock, valued at approximately $99,208.50. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Aquestive Therapeutics Stock Up 9.5%

AQST stock traded up $0.34 during trading hours on Friday, hitting $3.91. The company’s stock had a trading volume of 3,962,404 shares, compared to its average volume of 2,592,764. The company has a market capitalization of $491.45 million, a PE ratio of -6.11 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 12 month low of $2.93 and a 12 month high of $6.74. The stock has a 50 day moving average price of $4.37 and a two-hundred day moving average price of $4.22.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $7.56 million for the quarter, compared to analysts’ expectations of $11.02 million. Sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Hedge funds have recently modified their holdings of the company. Blue Owl Capital Holdings LP raised its holdings in Aquestive Therapeutics by 47.5% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 1,390,632 shares of the company’s stock worth $6,439,000 after buying an additional 447,700 shares during the period. StoneX Group Inc. bought a new stake in shares of Aquestive Therapeutics during the third quarter worth $70,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Aquestive Therapeutics during the 3rd quarter worth about $30,000. Profund Advisors LLC raised its position in Aquestive Therapeutics by 497.9% in the 3rd quarter. Profund Advisors LLC now owns 195,758 shares of the company’s stock valued at $906,000 after buying an additional 163,019 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Aquestive Therapeutics by 14.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,901 shares of the company’s stock valued at $107,000 after purchasing an additional 2,936 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the company. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday, October 16th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.75.

Check Out Our Latest Stock Analysis on Aquestive Therapeutics

Aquestive Therapeutics Company Profile

(Get Free Report)

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.

Read More

Insider Buying and Selling by Quarter for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.